Clinical Trial Update: Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating donor-derived anti-leukemia cytotoxic T lymphocytes for preventing relapse after haploidentical stem cell transplantation in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia

Drugs mentioned

• donor-derived anti-leukemia cytotoxic T lymphocytes

Snippet

Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia | Conditions: Acute Lymphoblastic Leukemia ALL, Acute Myeloid Leukemia (AML) | Phase 1, Phase 2 | Status: COMPLETED